New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
07:26 EDTILMN, RHHBYIllumina downgraded to Neutral from Outperform at RW Baird
RW Baird downgraded Ilumina as the firm believes that the outlook for the company's partnership with BGI has been clouded, and notes that a potential takeover of Ilumina by Roche (RHHBY) fell through previously. Target $54.
News For ILMN;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
07:19 EDTRHHBYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTILMN, RHHBYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBY, ILMNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
October 16, 2014
14:47 EDTRHHBYRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
10:01 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
05:33 EDTILMNIllumina upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
October 15, 2014
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
06:32 EDTILMNIllumina to invest in three genomics industry startups
Illumina selected three startup companies for the inaugural Illumina Accelerator funding cycle. The companies are Encoded Genomics, EpiBiome and Xcell Biosciences. The Illumina Accelerator will provide selected startups with seed investment, business guidance, access to Illumina’s sequencing systems and reagents, and fully operational lab space in the San Francisco Bay Area during the six-month cycle.
October 14, 2014
11:23 EDTRHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
08:15 EDTILMNIllumina should report stronger than expected results, says Wedbush
Subscribe for More Information
October 8, 2014
11:31 EDTRHHBYFDA grants priority review for Genentech's Lucentis
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. FDA has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7M Americans. The FDA confirmed action date is February 6, 2015. The sBLA was submitted August 7 to address the unmet need for approved ocular medications for the treatment of diabetic retinopathy. If approved by the FDA, Lucentis could be the first eye medicine available for diabetic retinopathy patients. The submission is based on results of the RISE and RIDE Phase III trials in which meaningful improvements in the disease were observed in a clinically significant proportion of diabetic retinopathy patients treated with Lucentis at two years compared to patients treated with sham injections. Benefits of Lucentis treatment were maintained during year three of treatment. The safety in the RISE and RIDE Phase III trials was consistent with previous studies.
10:55 EDTRHHBYLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
07:19 EDTRHHBYCBI to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use